Investor Relations
TSXV:NRX | OTCQB:NRXBF | FSE: J90
Transforming Regenerative Medicine
Nurexone's mission is to pioneer regenerative medicine targeting nerve and tissue regeneration for recovery from Spinal Cord Injuries (SCI), Traumatic Brain Injury (TBI) and a wide variety of indications.
We're developing ExoPTEN, a first nanodrug aimed at motor, sensory and functional recovery form acute spinal cord injury
Get Investor Updates
Financials & Filings
2025
2024
2023
2022
Latest News
November 12, 2025
NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
November 3, 2025
NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
October 21, 2025
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK
Presentations
Latest
Presentation
One Pager
Optic Nerve
One Pager
Exo-Top
One Pager
ISEV TECH
Fact Sheet
AAEV
September 9, 2025
NRXBF: US Patent Awarded for Cell Technology
By Zacks Small Cap Research
August 11, 2025
NRXBF: Company Treatment Outperforms Industry Standard
By Zacks Small Cap Research
July 8, 2025
NRXBF: Test Results Show Spinal Injury Recovery
By Zacks Small Cap Research
May 27, 2025
NRXBF: Company Remains Disciplined Amid Progress
By Zacks Small Cap Research
April 10, 2025
NRXBF: Critical Year Starts with Company in Good Shape
By Zacks Small Cap Research
March 17, 2025
NRXBF: Tests Confirm Potential for Spinal Cord Injury Recovery
By Zacks Small Cap Research
FRC provides fee-based coverage
December 11, 2024
Initiating Coverage: A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment
By Fundamental Research Corp.
October 2, 2024
Initiating Coverage: Potential Breakthrough Treatment for Spinal Injuries
By Zacks Small Cap Research
Analyst Reports
Events
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
|
26
|
28
|
29
|
30
|
31
|
1
| |
|
2
|
3
|
5
|
7
|
8
| ||
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
27
|
28
|
29
| |
|
30
|
2
|
3
|
4
|
5
|
6
|
